Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Alirocumab by Regeneron Pharmaceuticals for Sepsis: Likelihood of Approval
Alirocumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Sepsis. According to GlobalData, Phase I...
Vidutolimod by Regeneron Pharmaceuticals for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Vidutolimod by Regeneron Pharmaceuticals for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...
Vidutolimod by Regeneron Pharmaceuticals for Oropharyngeal Cancer: Likelihood of Approval
Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Vidutolimod by Regeneron Pharmaceuticals for Laryngeal Cancer: Likelihood of Approval
Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...
Vidutolimod by Regeneron Pharmaceuticals for Hypopharyngeal Cancer: Likelihood of Approval
Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
Vidutolimod by Regeneron Pharmaceuticals for Solid Tumor: Likelihood of Approval
Vidutolimod is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Solid Tumor. According to GlobalData, Phase...
Linvoseltamab by Regeneron Pharmaceuticals for Refractory Multiple Myeloma: Likelihood of Approval
Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Refractory Multiple Myeloma. According to GlobalData, Pre-Registration...
Linvoseltamab by Regeneron Pharmaceuticals for Relapsed Multiple Myeloma: Likelihood of Approval
Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Relapsed Multiple Myeloma. According to GlobalData, Pre-Registration...
Pozelimab by Regeneron Pharmaceuticals for Myasthenia Gravis: Likelihood of Approval
Pozelimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...
Dupilumab by Regeneron Pharmaceuticals for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Chronic Obstructive Pulmonary Disease (COPD). According to...
DB-OTO by Regeneron Pharmaceuticals for Deafness: Likelihood of Approval
DB-OTO is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Deafness. According to GlobalData, Phase II...
NTLA-2001 by Regeneron Pharmaceuticals for Familial Amyloid Cardiomyopathy: Likelihood of Approval
NTLA-2001 is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Familial Amyloid Cardiomyopathy. According to GlobalData,...
Nezastomig by Regeneron Pharmaceuticals for Renal Cell Carcinoma: Likelihood of Approval
Nezastomig is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
REGN-9933 by Regeneron Pharmaceuticals for Venous Thromboembolism: Likelihood of Approval
REGN-9933 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Venous Thromboembolism. According to GlobalData, Phase...
REGN-7999 by Regeneron Pharmaceuticals for Iron Deficiency Anemia: Likelihood of Approval
REGN-7999 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Iron Deficiency Anemia. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Fianlimab?
Fianlimab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Squamous Non-Small Cell Lung...
Risk adjusted net present value: What is the current valuation of Regeneron Pharmaceuticals's Linvoseltamab?
Linvoseltamab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Pre-Registration program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma....
REGN-5093M114 by Regeneron Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval
REGN-5093M114 is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Sarilumab by Regeneron Pharmaceuticals for Polyarticular Juvenile Idiopathic Arthritis (PJIA): Likelihood of Approval
Sarilumab is under clinical development by Regeneron Pharmaceuticals and currently in Pre-Registration for Polyarticular Juvenile Idiopathic Arthritis (PJIA). According to...